MediWound (NASDAQ:MDWD) Stock Price Crosses Above Fifty Day Moving Average of $16.98

Shares of MediWound Ltd. (NASDAQ:MDWDGet Free Report) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $16.98 and traded as high as $17.25. MediWound shares last traded at $16.47, with a volume of 46,671 shares trading hands.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MDWD. HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of MediWound in a report on Thursday, May 30th. StockNews.com upgraded MediWound to a “sell” rating in a report on Wednesday, May 8th.

View Our Latest Report on MDWD

MediWound Stock Performance

The stock has a market capitalization of $152.91 million, a price-to-earnings ratio of -11.93 and a beta of 0.72. The company has a 50 day moving average of $16.98 and a 200 day moving average of $14.11.

MediWound (NASDAQ:MDWDGet Free Report) last released its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. The firm had revenue of $5.34 million during the quarter, compared to analysts’ expectations of $5.33 million. As a group, research analysts expect that MediWound Ltd. will post -2.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Essex Investment Management Co. LLC grew its stake in MediWound by 241.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after purchasing an additional 93,705 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. boosted its position in shares of MediWound by 45.7% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after acquiring an additional 39,348 shares in the last quarter. Sargent Investment Group LLC boosted its position in shares of MediWound by 7.0% during the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after acquiring an additional 7,125 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in shares of MediWound by 7.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after acquiring an additional 6,200 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in shares of MediWound during the 1st quarter worth about $427,000. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

(Get Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Read More

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.